3,064,407 unregistered common shares sold to Glaxo Group at $36.50
By Devika Patel
Knoxville, Tenn., July 30 - Theravance Inc. negotiated a $111.85 million private placement of stock with Glaxo Group Ltd. on July 30, according to an 8-K filed Tuesday with the Securities and Exchange Commission.
The company will sell 3,064,407 unregistered common shares at $36.50 per share. The price per share is identical to the July 29 closing share price.
Settlement is expected Aug. 2.
Theravance is a South San Francisco, Calif.-based biopharmaceutical company.
| Issuer: | Theravance Inc.
|
| Issue: | Unregistered common stock
|
| Amount: | $111,850,856
|
| Shares: | 3,064,407
|
| Price: | $36.50
|
| Warrants: | No
|
| Investor: | Glaxo Group Ltd.
|
| Pricing date: | July 30
|
| Settlement date: | Aug. 2
|
| Stock symbol: | Nasdaq: THRX
|
| Stock price: | $36.50 at close July 29
|
| Market capitalization: | $3.57 billion
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
